Eleven Therapeutics Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Eleven Therapeutics Ltd. - overview
Established
2020
Location
Tel Aviv, -, Israel
Primary Industry
Biotechnology
About
Based in Tel Aviv, Israel, and founded in 2020, by Prof. Yaniv Erlich, Shaul Ilan, and Prof. Greg Hannon, Eleven Therapeutics Ltd. , aka Eleven Therapeutics, operates as a biotechnology company that primarily offers a combination of chemistry and artificial intelligence (AI) for RNA interference (RNAi) drug development.
In August 2022, Eleven Therapeutics Ltd. raised USD 22 million in a Seed funding led by Bill & Melinda Gates Foundation Trust, with participation from Entrée Capital, Harel Insurance Investments, Innovate UK, Kindred Capital, and NFX. Eleven Therapeutics offers SCSI-RNA, a programmable molecule used for analyzing diseases or biological targets of interest, as well as generating functional data about the activity profile of an unprecedented scale of siRNA (small interfering RNAs) molecules. The company also offers TERÅ beads (topologically encoded, RNA-active) platform to boost the performance of oligonucleotide therapeutics by creating DNA barcodes on each bead that record the pattern of these RNA modifications and make them available to high throughput sequencing.
Current Investors
Gates Foundation Trust, Harel Insurance Investments, Entree Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.eleventx.com
Verticals
Artificial Intelligence
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.